Prostate Specific Antigen Density of the Transition Zone: A New Effective Parameter for Prostate Cancer Prediction
- 1 April 1997
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 157 (4) , 1315-1321
- https://doi.org/10.1016/s0022-5347(01)64961-9
Abstract
Purpose: Use of prostate specific antigen (PSA) density to enhance the predictive value of detecting prostate cancer at intermediate PSA levels has been limited due to contradictory results in large scale studies. Most PSA leakage from the benign prostate into the serum comes from the transition zone. Therefore, in patients with benign prostatic hyperplasia (BPH) and prostate cancer with a serum PSA of less than 10 ng./ml. we studied and compared the values of PSA density of the total prostate and the transition zone. We examined the ability of PSA density of the transition zone to enhance prostate cancer detection in patients with intermediate PSA levels. Materials and Methods: The volumes of the entire prostate and of the transition zone were determined by transrectal ultrasound. PSA density for both regions was calculated in 88 patients with histologically confirmed prostate cancer (radical prostatectomy), and 74 with BPH and histologically proved benign disease. Results: Average total prostate PSA density plus or minus standard deviation was 0.12 +/− 0.07 and 0.22 +/− 0.12 ng./ml./cc in patients with BPH and prostate cancer, respectively, while average PSA density of the transition zone was 0.21 +/− 0.13 and 1.02 +/− 0.70 ng./ml./cc, respectively (p <0.0001). If a total prostate PSA density of 0.15 had been chosen, the cancer would have been missed in 34% of the patients compared to 10% if a cutoff value of 0.35 for PSA density of the transition zone had been chosen (p <0.001). Overall, in patients with a PSA of 0.25 to 10.0 ng./ml. the sensitivity and specificity of PSA density of the transition zone for predicting prostate cancer at a 0.35 cutoff value were 90 and 93%, respectively, compared to 94 and 89%, respectively, for those with a PSA of 4 to 10 ng./ml. Conclusions: In our study PSA density of the transition zone was much more accurate in predicting prostate cancer than was total prostate PSA density for PSA levels of less than 10 ng./ml. With respect to the high sensitivity and specificity, if confirmed in large prospective studies, including patients seen for early diagnosis, PSA density of the transition zone could become a routine tool for urologists in the prediction of prostate cancer in men with a PSA of 4 to 10 ng./ml.Keywords
This publication has 22 references indexed in Scilit:
- Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screeningPublished by American Medical Association (AMA) ,1995
- Free, Complexed and Total Serum Prostate Specific Antigen: The Establishment of Appropriate Reference Ranges for their Concentrations and RatiosJournal of Urology, 1995
- The Lack of Predictive Value of Prostate Specific Antigen Density in the Detection of Prostate Cancer in Patients with Normal Rectal Examinations and Intermediate Prostate Specific Antigen LevelsJournal of Urology, 1995
- Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigenUrology, 1995
- Correlation Between Serum Prostate Specific Antigen Levels and the Volume of the Individual Glandular Zones of the Human ProstateJournal of Urology, 1995
- Prostate-specific antigen: Critical issuesUrology, 1994
- Volume determinations of the whole prostate and of adenomas by transrectal ultrasound in patients with clinically benign prostatic hyperplasia: correlation of resected weight, blood loss and duration of operationBritish Journal of Urology, 1994
- Prospective evaluation of prostate-specificantigen density and systematic biopsies for early detection of prosttic carcinomaUrology, 1994
- Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference rangesJAMA, 1993
- Measurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate CancerNew England Journal of Medicine, 1991